Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib versus investigator's choice immunotherapy or observation after resection in KRAS G12C-positive stage II-IIIB NSCLC
jRCT2051260138Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of divarasib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Disease-free survival. Planned start Dec 2026; status: recruiting.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051260138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260138.